This study aims to investigate the effects of consuming fermented pea- and legume-based product on gut and overall human health. It is a randomized, single-blinded, controlled, cross-over trial with a dietary intervention. A total of 100 participants will be enrolled in this study and they will eat both fermented and unfermented pea- and legume-based products for three weeks. Participants will eat their habitual diet between the dietary intervention periods (wash-out). During the study, participants' perceived health, inflammatory markers, glucose and lipid metabolism, tryptophan metabolites, gastrointestinal symptoms, and gut microbiota will be assessed.
Plant-based protein sources, such as those derived from peas and legumes, are experiencing high demand due to their role in reducing reliance on animal products and promoting a more sustainable food system. Despite this, there is limited information available regarding the impact of components like fibre in plant-based foods on protein and other nutrients' metabolism. In addition, the evidence of the health effects of meat alternatives is still scarce. Food fermentation emerges as a potential solution to enhance the absorption of plant-based protein and various nutrients in the small intestine. This is achieved by reducing antinutrients and facilitating the absorption process. Additionally, food fermentation has implications for the composition and metabolic activity of the gut microbiota, influencing metabolism, immune responses, intestinal function, and overall health. The metabolism of tryptophan in the gut, modulated by the gut microbiota and the production of various metabolites, may serve as a key link in these observed health effects. The fermentation of plant-based foods potentially enhances their beneficial health effects, and investigating this contributes to an increased understanding of the gut-mediated health effects of foods and the mechanisms behind them. This study is part of a European research project HealthFerm. Detailed objectives are to: 1. compare fermented and unfermented pea- and legume-based food products on blood lipid and glucose metabolism and gastrointestinal comfort as well as perceived and observed overall well-being. 2. study the effects of fermented and unfermented pea- and legume-based food consumption on gut permeability and inflammation markers. 3. study the difference in microbiota composition, diversity, and its contribution to cardiometabolic outcomes after consuming fermented and unfermented pea- and legume-based food products . 4. study the difference in microbiota-related metabolites, especially tryptophan metabolites, between fermented and unfermented pea- and legume-based food products. A total of 100 participants will be enrolled in this randomized, single-blinded, controlled, cross-over trial, during which they will eat both fermented and unfermented pea- and legume-based products as part of their habitual diet. The study follows this sequence: Weeks 1-3: Habitual diet Weeks 4-6: Intervention diet 1 Weeks 7-9: Habitual diet (wash-out) Weeks 10-12: Intervention diet 2 Fasting blood, urinary and faecal samples, as well as food diaries and questionnaires, are collected at the end of each study period to assess participants' diet, perceived health, gastrointestinal symptoms, inflammatory markers, glucose and lipid metabolism, tryptophan metabolites, and gut microbiota composition and their metabolites, such as short-chain fatty acids. In addition, participants' values and attitudes towards fermented foods are assessed. At the end of the study, participants will receive their laboratory results and dietary guidance for their habitual diet from a registered dietitian.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
100
Participants incorporate a novel fermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
Participants incorporate an unfermented product into their habitual diet for three weeks. The product replaces the main protein source of the meal(s). Participants will receive dietary guidance on how to follow the intervention diet, as well as potential supplement recommendations provided by the authorized nutritionist.
Institute of Public Health and Clinical Nutrition, University of Eastern Finland
Kuopio, Finland
P-hs-CRP (mg/l)
Time frame: Weeks 3, 6, 9, and 12
IL-22
Time frame: Weeks 3, 6, 9, and 12
LBP (μg/ml)
Time frame: Weeks 3, 6, 9, and 12
Changes in the composition gut microbiota
Composition of gut microbiota will be analysed from faecal samples
Time frame: Weeks 3, 6, and 12
Short-chain fatty acids assessed from plasma samples
Time frame: Weeks 3, 6, 9, and 12
Glucose metabolism
fP-Gluk and B-HbA1C (mmol/l)
Time frame: Weeks 3, 6, 9, and 12
fP-Insu (mU/l)
Time frame: Weeks 3, 6, 9, and 12
Lipid metabolism
fP-Kol, fP-Kol-HDL, fP-Kol-LDL, fP-Trigly, and fP-FFA (mmol/l)
Time frame: Weeks 3, 6, 9, and 12
Tryptophan metabolism
Tryptophan metabolites will be analysed with non-targeted metabolomics.
Time frame: Weeks 3, 6, 9, and 12
Self-reported overall health (Short Form-36 Health Survey, SF-36)
Different sections are rated from 0 to 100 points, where higher scores mean better perceived health.
Time frame: Weeks 3, 6, 9, and 12
Self-reported mental health (General Health Questionnaire-12, GHQ-12)
The questionnaire is rated from 0 to 12 points, where higher score means greater psychological distress.
Time frame: Weeks 3, 6, 9, and 12
Self-reported gastrointestinal symptoms (Gastrointestinal Symptoms Rating Scale, GSRS)
Different symptoms in the questionnaire are rated from 0 to 7, where higher score means greater symptoms.
Time frame: Weeks 3, 6, 9, and 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.